Overview

* Enveric Q3 net loss at $3.4 mln, EPS at -$10.81

* Completed reverse stock split to address Nasdaq bid price deficiency

Outlook

* Enveric plans to submit IND application for EB-003 in 2026

* Company aims for first-in-human trial of EB-003 in 2026

Result Drivers

* HEADQUARTERS RELOCATION - Relocated to Cambridge, MA to leverage the biotech hub for advancing EB-003

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$10.81

Q3 Net -$3.4

Income mln

Analyst Coverage

* Wall Street's median 12-month price target for Enveric Biosciences Inc ( ENVB ) is $120.00, about 95.5% above its November 13 closing price of $5.46

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)